Background Refractory ascites is a severe complication of liver cirrhosis and treatment
options consist in large volume paracentesis, transjugular intrahepatic portosystemic shunt …

Ascites remains a significant challenge in patients with cirrhosis, posing difficulties in
management and affecting prognosis. This review examines the current understanding of …

Background/Aim: The management of refractory ascites is critical for the treatment of patients
with decompensated cirrhosis. This study aimed to evaluate the feasibility and safety of cell …

Background Treatment of refractory ascites in liver cirrhosis is challenging. Transjugular
intrahepatic portosystemic shunt and alfapump® have been proposed for the management …

Ascites is the most common complication of cirrhosis, impairs quality of life, and carries a
poor prognosis. Transjugular intrahepatic portosystemic shunt (TIPS) is a well-validated …

For patients with cirrhosis, no definitive predictor of the efficacy and prognosis of tolvaptan
treatment exists. We assessed the cisterna chyli's utility as an optimal marker. We …

Cirrhosis affects 4.5 million people in the United States. 1 Sequela of cirrhosis and portal
hypertension include varices, which occur in up to 60 to 80% of cirrhotic patients and pose a …

Refractory ascites (RA) refers to ascites that cannot be mobilized or that has an early
recurrence that cannot be prevented by medical therapy. Every year, 5–10% of patients with …

Low‐flow removal of refractory ascites is critical to treating cirrhosis and digestive system
tumor, and thus, commercial ascites pump emerged lately. The rigid structure of clinically …

For cirrhotic refractory ascites, diuretics combined with albumin and vasoactive drugs are the
first-line choice for ascites management. However, their therapeutic effects are limited, and …